PÁCAL, Lukáš, Katarína CHALÁSOVÁ, Anna PLESKAČOVÁ, Jitka REHOROVA, Josef TOMANDL and Kateřina KAŇKOVÁ. Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology. International Journal of Molecular Sciences. Basel, Switzerland: MDPI AG, 2018, vol. 19, No 5, p. 1-9. ISSN 1422-0067. Available from: https://dx.doi.org/10.3390/ijms19051517.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Deleterious Effect of Advanced CKD on Glyoxalase System Activity not Limited to Diabetes Aetiology
Authors PÁCAL, Lukáš (203 Czech Republic, guarantor, belonging to the institution), Katarína CHALÁSOVÁ (703 Slovakia, belonging to the institution), Anna PLESKAČOVÁ (203 Czech Republic, belonging to the institution), Jitka REHOROVA (203 Czech Republic), Josef TOMANDL (203 Czech Republic) and Kateřina KAŇKOVÁ (203 Czech Republic, belonging to the institution).
Edition International Journal of Molecular Sciences, Basel, Switzerland, MDPI AG, 2018, 1422-0067.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10608 Biochemistry and molecular biology
Country of publisher Switzerland
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 4.183
RIV identification code RIV/00216224:14110/18:00101254
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.3390/ijms19051517
UT WoS 000435297000253
Keywords in English glyoxalase; diabetes; chronic kidney disease; diabetic nephropathy
Tags 14110512, 14110518, EL OK, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 9/2/2019 22:00.
Abstract
Methylglyoxal production is increased in diabetes. Methylglyoxal is efficiently detoxified by enzyme glyoxalase 1 (GLO1). The aim was to study the effect of diabetic and CKD milieu on (a) GLO1 gene expression in peripheral blood mononuclear cells; (b) GLO1 protein levels in whole blood; and (c) GLO1 activity in RBCs in vivo in diabetic vs. non-diabetic subjects with normal or slightly reduced vs. considerably reduced renal function (CKD1-2 vs. CKD3-4). A total of 83 subjects were included in the study. Gene expression was measured using real-time PCR, and protein levels were quantified using Western blotting. Erythrocyte GLO1 activity was measured spectrophotometrically. GLO1 gene expression was significantly higher in subjects with CKD1-2 compared to CKD3-4. GLO1 protein level was lower in diabetics than in non-diabetics. GLO1 activity in RBCs differed between the four groups being significantly higher in diabetics with CKD1-2 vs. healthy subjects and vs. nondiabeticsfig with CKD3-4. GLO1 activity was significantly higher in diabetics compared to nondiabetics. In conclusion, both diabetes and CKD affects the glyoxalase system. It appears that CKD in advanced stages has prevailing and suppressive effects compared to hyperglycaemia. CKD decreases GLO1 gene expression and protein levels (together with diabetes) without concomitant changes of GLO1 activity.
Links
GA16-14829S, research and development projectName: Efekt diabetického mikroprostředí na vybrané procesy při vzniku kolorektálního karcinomu, jeho klinický průběh a odpověď na terapii
Investor: Czech Science Foundation
PrintDisplayed: 10/5/2024 00:11